Schrödinger reported a third-quarter net loss of $37.7 million, or $0.50 per share, compared to a $32.8 million loss in the prior year period. Total revenue increased 19% to $64.5 million, driven by a 19% rise in software revenue and a surge in drug discovery revenue to $24.2 million following a milestone payment from Structure Therapeutics. The company raised its full-year annual contract value guidance to a range of $222 million to $232 million and increased its drug discovery revenue outlook to $75 million–$85 million, citing strong demand for its computational platform. Schrödinger operates in the life sciences technology sector, providing software platforms and drug discovery services to pharmaceutical and biotechnology companies.
